These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33682494)

  • 41. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
    Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
    Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
    [No Abstract]   [Full Text] [Related]  

  • 44. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.
    Marinovich ML; Sardanelli F; Ciatto S; Mamounas E; Brennan M; Macaskill P; Irwig L; von Minckwitz G; Houssami N
    Breast; 2012 Oct; 21(5):669-77. PubMed ID: 22863284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluating pathologic response of breast cancer to neoadjuvant chemotherapy with computer-extracted features from contrast-enhanced ultrasound videos.
    Zhang Q; Yuan C; Dai W; Tang L; Shi J; Li Z; Chen M
    Phys Med; 2017 Jul; 39():156-163. PubMed ID: 28690116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MRI Volume Changes of Axillary Lymph Nodes as Predictor of Pathologic Complete Responses to Neoadjuvant Chemotherapy in Breast Cancer.
    Cattell RF; Kang JJ; Ren T; Huang PB; Muttreja A; Dacosta S; Li H; Baer L; Clouston S; Palermo R; Fisher P; Bernstein C; Cohen JA; Duong TQ
    Clin Breast Cancer; 2020 Feb; 20(1):68-79.e1. PubMed ID: 31327729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment.
    Bufi E; Belli P; Di Matteo M; Terribile D; Franceschini G; Nardone L; Petrone G; Bonomo L
    Eur J Radiol; 2014 Sep; 83(9):1631-8. PubMed ID: 24938669
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area.
    Rossi F; Torri L; Lambertini M; De Giorgis S; Calabrese M; Tagliafico AS
    Eur Radiol; 2020 Aug; 30(8):4234-4241. PubMed ID: 32232787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new algorithm for automatic vascular mapping of DCE-MRI of the breast: Clinical application of a potential new biomarker.
    Vignati A; Giannini V; Carbonaro LA; Bertotto I; Martincich L; Sardanelli F; Regge D
    Comput Methods Programs Biomed; 2014 Dec; 117(3):482-8. PubMed ID: 25262335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?
    Woolf DK; Taylor NJ; Makris A; Tunariu N; Collins DJ; Li SP; Ah-See ML; Beresford M; Padhani AR
    Br J Radiol; 2016 Jul; 89(1063):20150961. PubMed ID: 27187599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of Imaging and Treatment Monitoring of Breast Lesions with Three-Dimensional Shear Wave Elastography.
    Athanasiou A; Latorre-Ossa H; Criton A; Tardivon A; Gennisson JL; Tanter M
    Ultraschall Med; 2017 Jan; 38(1):51-59. PubMed ID: 25741668
    [No Abstract]   [Full Text] [Related]  

  • 52. Prediction of Chemoresistance in Women Undergoing Neo-Adjuvant Chemotherapy for Locally Advanced Breast Cancer: Volumetric Analysis of First-Order Textural Features Extracted from Multiparametric MRI.
    Panzeri MM; Losio C; Della Corte A; Venturini E; Ambrosi A; Panizza P; De Cobelli F
    Contrast Media Mol Imaging; 2018; 2018():8329041. PubMed ID: 29853811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
    Li H; Yao L; Jin P; Hu L; Li X; Guo T; Yang K
    Breast; 2018 Aug; 40():106-115. PubMed ID: 29758503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiomic analysis of DCE-MRI for prediction of response to neoadjuvant chemotherapy in breast cancer patients.
    Fan M; Wu G; Cheng H; Zhang J; Shao G; Li L
    Eur J Radiol; 2017 Sep; 94():140-147. PubMed ID: 28712700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
    Qu YH; Zhu HT; Cao K; Li XT; Ye M; Sun YS
    Thorac Cancer; 2020 Mar; 11(3):651-658. PubMed ID: 31944571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
    Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results.
    D'Angelo A; Rinaldi P; Belli P; D'Amico R; Carlino G; Grippo C; Giuliani M; Orlandi A; Infante A; Manfredi R
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):225-231. PubMed ID: 30657564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of the Intravoxel Incoherent Motion Diffusion Weighted Imaging in the Pre-treatment Prediction and Early Response Monitoring to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Che S; Zhao X; Ou Y; Li J; Wang M; Wu B; Zhou C
    Medicine (Baltimore); 2016 Jan; 95(4):e2420. PubMed ID: 26825883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.